Latest Headlines

Latest Headlines

Former Alere execs assemble $3.8B take-private offer

Former Alere executives are putting together a $46-per-share takeover offer for the diagnostics company, according to a Sept. 15 SEC filing. Investors didn't embrace the offer entirely, but they did send shares up about 13% to $41.33 in midafternoon trading.

Alere to complete strategic review by year-end

In the midst of a management transition, diagnostic company Alere missed its quarterly numbers. The company acknowledged its recent problems and missteps as well as started to outline a new strategic vision for Alere that will become clearer to investors around the end of this year, when a comprehensive review will be finished.

Alere rethinks BBI IPO

So much for those IPO plans. Alere last week decided against taking its BBI Diagnostics businesses public on the London Stock Exchange, citing equity market conditions in the U.K.

Alere gets FDA clearance for rapid influenza test

Alere's i Influenza A & B test, which the company says is the first and only molecular test to detect and differentiate beween the two types, received FDA clearance on June 16.

It's official: Alere is spinning off its diagnostics biz

BBI Diagnostics Group provided details off its plans to be traded on the London Stock Exchange in June 2014 in a May 19 statement. The IPO will consist of the sale of the 25% indirect ownership interest in BBI held by parent company Alere. 

Alere recalls test strips after patient deaths

In reaction to three patient deaths associated with its INRatio2 PT/INR Professional Test Strips, Alere initiated a voluntary Class I recall of the products.

Alere shakes up boardroom, embarks on strategic review

Still finding its footing after irked investors mounted a proxy challenge last year, Alere is shuffling its top ranks and setting out on a review of its operations, a move that could spell more divestitures.

Alere plans to spin off a subsidiary in a U.K. IPO

In the wake of bitter proxy fight, diagnostics leader Alere revealed plans to trim off some its noncore businesses, planning an IPO in an effort to keep its promise to investors worried about the company's mounting debts.

Alere improves Q4 numbers through revenue growth and cost cuts

Alere's 2013 fourth quarter reflected a healthy boost in revenue and a drastic reduction in net losses over a year ago. The gains came, in part, from organic growth and cutting costs in areas including research and development and administration.

Alere's new HIV test could gain momentum from Affordable Care Act

If timing is everything, then Alere stands to gain plenty, thanks to the Affordable Care Act. The new law mandates reimbursement for HIV testing from both public and private insurers, and Alere recently rolled out a new, first-of-its-kind combo HIV diagnostic in the U.S.